<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968224</url>
  </required_header>
  <id_info>
    <org_study_id>R-2016-785-094</org_study_id>
    <nct_id>NCT03968224</nct_id>
  </id_info>
  <brief_title>Effectiveness of Dapagliflozin for Weight Loss</brief_title>
  <official_title>Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Medico Nacional Siglo XXI IMSS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Medico Nacional Siglo XXI IMSS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mexico has one of the highest prevalence of obesity, reported on 32.4 percent of people over
      20 years old, according to National Health and Nutrition Examination Survey (ENSANUT) 2012.
      This implies that 22 million Mexicans have a grade of obesity. According to the ENSANUT 2012,
      the prevalence of obesity class III is 1.8 percent (1.5 to 2.1) on males and 4.1 percent (3.7
      to 4.5) on females.

      In 2008, a multidisciplinary clinic focused on treating severe obesity and its related
      comorbidities was inaugurated at Specialities' Hospital from the National Medical Center
      21^st century. Currently, the &quot;Obesity Clinic&quot; tends to 400 patients, of whom 150 have
      undergone bariatric surgery (laparoscopic gastric bypass or gastric sleeve), 250 patients are
      on waiting list and/or preparation for this procedure, and up to 10 first time appointments
      per month are provided to asses the admission to the clinic. The requirements for admission
      are: body mass index (BMI) greater than 35 kg/m^2 with a major comorbidity (diabetes,
      hypertension, dyslipidemia or obstructive sleep apnea syndrome) or obesity class III.
      According to our previous data the mean age of these patients is 41 years, 46 percent have
      pre-diabetes or type 2 diabetes mellitus; 66 percent has hypertension and 33 percent has
      dyslipidemia (hypertriglyceridemia, hypoalphalipoproteinemia or both). The management of
      alterations in the glucose metabolism (prediabetes or diabetes) in this unit is made by
      dietary treatment supervised by the Nutrition Service of the Obesity Clinic and with the use
      of metformin at doses of 1,700 mg/day and/or basal insulin (mainly, Neutral Protamine
      Hagedorn insulin).

      A group of drug products known as sodium-glucose co-transporter 2 inhibitors (iSGLT2) has
      been recently approved for type 2 diabetes treatment. This low-affinity and high capacity
      transporter is found in the apical part of the epithelium cells in the proximal convoluted
      tubules (section S1) and it is responsible of 90 percent of the glucose re-absorption
      (remaining 10 percent is reabsorbed by the SGLT1); therefore, its inhibition induces
      glycosuria and subsequently reductions in plasmatic glucose. Dapagliflozin is a selective
      SGLT2 inhibitor than has shown a sustained effect on the reduction of glycated hemoglobin
      (HbA1c) at 0.4 to 0.8 percent (with initial HbA1c at 7.8 to 8.0 percent). Additionally, due
      to the induction of glycosuria up to 20 to 85 g/day, it has been calculated that its use
      induces a caloric deficit at 80 to 340 kcal/day. This has been tested in patients with type 2
      diabetes in which induces a weight loss of 2 to 3 kg and in combination with metformin even a
      weight loss up to 5.07 kg (-6.21 to 3.93 kg) without regain (at least for 2 years) as
      previously demonstrated. Furthermore, dapagliflozin decrease systolic blood pressure at 4 to
      5 mmHg, increases HDL cholesterol concentrations at 1.8 to 4.4 percent and decreases
      triglyceride concentration at 2.4 to 6.2 percent. The drug product action is independent of
      the insulin production at pancreas, consequently, it exists a possibility of using the drug
      product on patients with prediabetes or even on other types of diabetes. Regarding the
      adverse effects related to its use, it has been described increase in the risk of
      genitourinary infections with a low risk for inducing hypoglycemia. Previous studies have
      demonstrated no kidney damage generation, although it is contraindicated in patients with
      chronic kidney disease, as well as patients with repeated urinary infections, preexisting
      fluid and electrolyte imbalance or dehydration risk.

      A previous study that included 182 patients with type 2 diabetes inadequately controlled with
      metformin (HbA1c average 7.17 percent) assessed the effect of dapagliflozin 10 mg in total
      weight after 24 weeks compared to placebo. It was found a decrease in weight of 2.08 kg (2.8
      to 1.31 kg, p&lt;0.001), decrease in waist circumference of 1.52 cm (2.74 to 0.31, p=0.014),
      decrease in total fat mass assessed with densitometry (DEXA) of 1.48 kg (2.22 to 0.74,
      p=0.001), decrease of visceral fat mass of 258.4 cm^3 (448.1 to 68.6, p=0.008) and
      subcutaneous fat of 184.9 cm^3 (359.7 to 10.1, p=0.03). Most of these studies on weight and
      metabolic control have been performed in patients with obesity class II or I.

      The aim of this study is to assess if dapagliflozin in combination with metformin is at least
      10 percent more effective for weight reduction in comparison with metformin in patients with
      prediabetes or type 2 diabetes and obesity grade III.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

      A convenience sampling will be done for patients diagnosed with diabetes or prediabetes
      according to the American Diabetes Association (ADA) criteria, who assist to the Obesity
      Clinic and meet the selection criteria. Data from patients that during the study protocol are
      called to undergo bariatric surgery procedure will be used until the time of surgery
      (intention-to-treat analysis). The prevalence of comorbidities at baseline and the type and
      dose of drugs used for treatment will be recorded. Patients will be randomized by a random
      numbers system generated with a computational software and will be assigned to a group:
      metformin (1,700 mg/day) or metformin (1,700 mg/day) and dapagliflozin 10 mg. All patients
      will receive dietary treatment and follow-up during the study by the Nutrition Service. Once
      assigned to the corresponding group, patients will receive an identification code that will
      be retained throughout the study. One of the researchers not directly involved in patient
      care, will assign tablets needed for daily intake for a month and then the number of tablets
      required for 3 months in a sealed envelope. A run-in period will be used to assess tolerance
      to treatments. This period will be for a month. At this time patients may notice an increase
      of uresis and will be instructed to increase fluid intake. Anthropometric and biochemical
      variables will be recorded baseline and at 1, 3, 6 and 12 months. The determination of
      glucagon, ghrelin, adiponectin, resistin, interleukin 6 (IL-6) and interleukin 10 (IL-10)
      will be held on initial appointment and before surgery (depending on the response of each
      patient). For the determination of these cytokines and peptides, an ELISA kit (Enzyme Linked
      Immunosorbent Assay) will be used. Adherence to treatment will be evaluated and will consist
      in consumption of 90 percent of pills granted. The patient will be required to return the
      drug blister. The registration of adverse events will take place from the start of treatment
      and throughout the study. Each event will be evaluated by researchers and classified
      according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 list.
      CTCAE considers that an adverse event grade 4 or 5 indicates discontinuation of treatment;
      grade 3 must be submitted to review by the medical team, and grades 1 or 2 require
      registration and intervention but not discontinuation of treatment. Adverse events will be
      recorded in the report sheet. An intention-to-treat analysis will be used if patients require
      treatment with insulin or sulfonylureas (grade 3 adverse event). They will provide
      information until the time of its inception. Patients who do not achieve weight loss at one
      year follow-up, will be discarded to their primary care hospital for continue with dietary
      recommendations.

      Sample Size:

      A convenience sample will be performed of patients with obesity class III and prediabetes or
      diabetes according ADA criteria at Obesity Clinic who meet selection criteria. The sample
      size was calculated using a mean difference formula with data from Zhang et al. who evaluated
      weight loss in patients using metformin/dapagliflozin and compared with placebo. Sample size
      required is 90 patients: 45 patients in metformin group and 45 patients in
      dapagliflozin/metformin group. Considering a loss of 20 percent of population during study,
      the final sample size required is 108 patients: 54 patients in metformin and 54 patients in
      dapagliflozin group.

      Statistical analysis Quantitative variables will be presented as means and standard deviation
      or median with interquartile ranges according to data distribution. Qualitative variables
      will be presented as frequencies or percentages. For assessing data distribution, a
      Shapiro-Wilk test will be performed. Association between quantitative variables will be
      assessed through Repeated measures ANOVA and qualitative variables with McNemar test.
      Statistical significance will be evaluated with p &lt; 0.05. Statistical analysis will be
      performed using statistical packages: Statistical Package for the Social Sciences (SPSS)
      version 17.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized single-blind controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 10 percent of initial weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 10 percent of initial blood pressure (systolic and diastolic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 10 percent of initial waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides level</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 10 percent of initial triglycerides levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Cytokines Level</measure>
    <time_frame>12 months</time_frame>
    <description>Change in interleukin-6, interleukin-10, adiponectin, and resistin, comparing initial versus final levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Metformin/Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1,700 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin/Metformin</intervention_name>
    <description>Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.</description>
    <arm_group_label>Metformin/Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI greater than or equal to 40 kg/m^2

          -  Diagnosis of diabetes or prediabetes according to the criteria of the ADA

          -  Patients who sign informed consent letter

        Exclusion Criteria:

          -  Use of insulin or sulfonylureas

          -  Chronic renal failure with glomerular filtration rate &lt;60 ml/min/1.73 m^2

          -  Use of loop diuretics with no possibility to suspend

          -  Active genitourinary tract infections determined by symptomatology or urinalysis

          -  Use of drugs for weight control

          -  Patients with untreated or uncontrolled hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moises Mercado, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Ferreira-Hermosillo, MSc</last_name>
    <phone>+52156276900</phone>
    <phone_ext>21551</phone_ext>
    <email>aldo.nagisa@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Especialidades Centro Médico Nacional Siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Ferreira-Hermosillo, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Mendoza-Zubieta, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Ramírez-Rentería, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario A Molina-Ayala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etual Espinosa-Cárdenas, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandra Albarrán-Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moisés Mercado, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aldo Ferreira-Hermosillo, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Barrera-Cruz A, Avila-Jiménez L, Cano-Pérez E, Molina-Ayala MA, Parrilla-Ortiz JI, Ramos-Hernández RI, Sosa-Caballero A, Sosa-Ruiz Mdel R, Gutiérrez-Aguilar J. [Practice clinical guideline. Prevention, diagnosis and treatment of overweight and obesity]. Rev Med Inst Mex Seguro Soc. 2013 May-Jun;51(3):344-57. Review. Spanish.</citation>
    <PMID>23883468</PMID>
  </reference>
  <reference>
    <citation>Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.</citation>
    <PMID>11234459</PMID>
  </reference>
  <reference>
    <citation>Mason EE, Doherty C, Maher JW, Scott DH, Rodriguez EM, Blommers TJ. Super obesity and gastric reduction procedures. Gastroenterol Clin North Am. 1987 Sep;16(3):495-502.</citation>
    <PMID>3436656</PMID>
  </reference>
  <reference>
    <citation>Nguyen NT, Ho HS, Palmer LS, Wolfe BM. Laparoscopic Roux-en-Y gastric bypass for super/super obesity. Obes Surg. 1999 Aug;9(4):403-6.</citation>
    <PMID>10484302</PMID>
  </reference>
  <reference>
    <citation>Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, Gómez-Humarán IM, Gaona-Pineda EB, Gómez-Acosta LM, Rivera-Dommarco JÁ, Hernández-Ávila M. [Methodological design of the National Health and Nutrition Survey 2016]. Salud Publica Mex. 2017 May-Jun;59(3):299-305. doi: 10.21149/8593. Spanish.</citation>
    <PMID>28902317</PMID>
  </reference>
  <reference>
    <citation>Barrera-Cruz A, Rodríguez-González A, Molina-Ayala MA. [The current state of obesity in Mexico]. Rev Med Inst Mex Seguro Soc. 2013 May-Jun;51(3):292-9. Spanish.</citation>
    <PMID>23883458</PMID>
  </reference>
  <reference>
    <citation>Rizzello M, De Angelis F, Campanile FC, Silecchia G. Effect of gastrointestinal surgical manipulation on metabolic syndrome: a focus on metabolic surgery. Gastroenterol Res Pract. 2012;2012:670418. doi: 10.1155/2012/670418. Epub 2012 Oct 22.</citation>
    <PMID>23133447</PMID>
  </reference>
  <reference>
    <citation>Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco JA. [Prevalence of obesity in Mexican adults 2000-2012]. Salud Publica Mex. 2013;55 Suppl 2:S151-60. Spanish.</citation>
    <PMID>24626691</PMID>
  </reference>
  <reference>
    <citation>Santo MA, Riccioppo D, Pajecki D, Cleva Rd, Kawamoto F, Cecconello I. Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity. Clinics (Sao Paulo). 2014;69(12):828-34. doi: 10.6061/clinics/2014(12)07.</citation>
    <PMID>25627995</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002. Review.</citation>
    <PMID>30559228</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102. doi: 10.2337/dc19-S009. Review.</citation>
    <PMID>30559235</PMID>
  </reference>
  <reference>
    <citation>Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD; Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62. doi: 10.1210/jc.2014-3415. Epub 2015 Jan 15. Erratum in: J Clin Endocrinol Metab. 2015 May;100(5):2135-6.</citation>
    <PMID>25590212</PMID>
  </reference>
  <reference>
    <citation>Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361. Review.</citation>
    <PMID>24231879</PMID>
  </reference>
  <reference>
    <citation>Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009 Feb;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. Review.</citation>
    <PMID>19125776</PMID>
  </reference>
  <reference>
    <citation>Shepherd PR, Kahn BB. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999 Jul 22;341(4):248-57. Review.</citation>
    <PMID>10413738</PMID>
  </reference>
  <reference>
    <citation>Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003 Jan;89(1):3-9. Review.</citation>
    <PMID>12568659</PMID>
  </reference>
  <reference>
    <citation>Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.</citation>
    <PMID>10480610</PMID>
  </reference>
  <reference>
    <citation>Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. 2005 Apr 22;76(23):2655-68.</citation>
    <PMID>15792833</PMID>
  </reference>
  <reference>
    <citation>Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008 Mar 13;51(5):1145-9. doi: 10.1021/jm701272q. Epub 2008 Feb 9.</citation>
    <PMID>18260618</PMID>
  </reference>
  <reference>
    <citation>Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.</citation>
    <PMID>19129749</PMID>
  </reference>
  <reference>
    <citation>Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. Epub 2010 Mar 3.</citation>
    <PMID>20200268</PMID>
  </reference>
  <reference>
    <citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.</citation>
    <PMID>30742570</PMID>
  </reference>
  <reference>
    <citation>List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.</citation>
    <PMID>19114612</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.</citation>
    <PMID>24919526</PMID>
  </reference>
  <reference>
    <citation>Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.</citation>
    <PMID>22446170</PMID>
  </reference>
  <reference>
    <citation>Orme M, Fenici P, Lomon ID, Wygant G, Townsend R, Roudaut M. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr. 2014 Jun 11;6:73. doi: 10.1186/1758-5996-6-73. eCollection 2014. Review.</citation>
    <PMID>25006351</PMID>
  </reference>
  <reference>
    <citation>Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-50. doi: 10.2337/dc13-0467. Epub 2013 Oct 21.</citation>
    <PMID>24144654</PMID>
  </reference>
  <reference>
    <citation>Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.</citation>
    <PMID>26474563</PMID>
  </reference>
  <reference>
    <citation>Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018 Dec;41(12):2552-2559. doi: 10.2337/dc18-1087. Epub 2018 Oct 23.</citation>
    <PMID>30352894</PMID>
  </reference>
  <reference>
    <citation>Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20.</citation>
    <PMID>25894829</PMID>
  </reference>
  <reference>
    <citation>Hattersley AT, Thorens B. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion. N Engl J Med. 2015 Sep 3;373(10):974-6. doi: 10.1056/NEJMcibr1506573.</citation>
    <PMID>26332554</PMID>
  </reference>
  <reference>
    <citation>Saponaro C, Pattou F, Bonner C. SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 2018 Nov;44(5):383-385. doi: 10.1016/j.diabet.2018.06.005. Epub 2018 Jun 30. Review.</citation>
    <PMID>30017776</PMID>
  </reference>
  <reference>
    <citation>Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015 Apr;6(2):61-7. doi: 10.1177/2042018814560735. Review.</citation>
    <PMID>25941564</PMID>
  </reference>
  <reference>
    <citation>Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9. doi: 10.1016/j.jash.2014.01.007. Epub 2014 Jan 26. Review.</citation>
    <PMID>24602971</PMID>
  </reference>
  <reference>
    <citation>Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5. Review.</citation>
    <PMID>29349558</PMID>
  </reference>
  <reference>
    <citation>Jayawardene D, Ward GM, O'Neal DN, Theverkalam G, MacIsaac AI, MacIsaac RJ. New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering? Heart Lung Circ. 2014 Nov;23(11):997-1008. doi: 10.1016/j.hlc.2014.05.007. Epub 2014 Jun 10. Review.</citation>
    <PMID>24996388</PMID>
  </reference>
  <reference>
    <citation>Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9.</citation>
    <PMID>11118008</PMID>
  </reference>
  <reference>
    <citation>Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015 Nov 1;471(3):307-22. doi: 10.1042/BJ20150497. Review.</citation>
    <PMID>26475449</PMID>
  </reference>
  <reference>
    <citation>Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005 Nov;7(6):654-65. Review.</citation>
    <PMID>16219009</PMID>
  </reference>
  <reference>
    <citation>Hermann LS, Karlsson JE, Sjöstrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol. 1991;41(3):263-5.</citation>
    <PMID>1748145</PMID>
  </reference>
  <reference>
    <citation>Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4.</citation>
    <PMID>7623903</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9.</citation>
    <PMID>7623902</PMID>
  </reference>
  <reference>
    <citation>Mogul HR, Peterson SJ, Weinstein BI, Zhang S, Southren AL. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Dis. 2001 Sep-Oct;3(5):285-92.</citation>
    <PMID>11975807</PMID>
  </reference>
  <reference>
    <citation>Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012 Aug;20(8):1645-52. doi: 10.1038/oby.2012.59. Epub 2012 Mar 8.</citation>
    <PMID>22402735</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract. 2014 Sep;105(3):313-21. doi: 10.1016/j.diabres.2014.06.006. Epub 2014 Jun 22. Review.</citation>
    <PMID>25015317</PMID>
  </reference>
  <reference>
    <citation>Nowak A, Czkwianianc E. A contemporary approach to body mass regulation mechanisms. Prz Gastroenterol. 2016;11(2):73-7. doi: 10.5114/pg.2016.60043. Epub 2016 May 19. Review.</citation>
    <PMID>27350833</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.</citation>
    <PMID>22238392</PMID>
  </reference>
  <reference>
    <citation>Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45. doi: 10.1146/annurev-immunol-031210-101322. Review.</citation>
    <PMID>21219177</PMID>
  </reference>
  <reference>
    <citation>Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C, Morales-González JA. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5):3117-32. doi: 10.3390/ijms12053117. Epub 2011 May 13. Review.</citation>
    <PMID>21686173</PMID>
  </reference>
  <reference>
    <citation>Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008 Dec;29(24):2959-71. doi: 10.1093/eurheartj/ehn387. Epub 2008 Sep 5. Review.</citation>
    <PMID>18775919</PMID>
  </reference>
  <reference>
    <citation>Kalupahana NS, Moustaid-Moussa N, Claycombe KJ. Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 2012 Feb;33(1):26-34. doi: 10.1016/j.mam.2011.10.011. Epub 2011 Oct 21. Review.</citation>
    <PMID>22040698</PMID>
  </reference>
  <reference>
    <citation>Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918. doi: 10.1155/2010/535918. Epub 2010 Aug 5.</citation>
    <PMID>20847813</PMID>
  </reference>
  <reference>
    <citation>Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev. 2007 May;65(5):251-6. Review.</citation>
    <PMID>17566551</PMID>
  </reference>
  <reference>
    <citation>Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005 Oct;113(9):534-7.</citation>
    <PMID>16235156</PMID>
  </reference>
  <reference>
    <citation>Patel PS, Buras ED, Balasubramanyam A. The role of the immune system in obesity and insulin resistance. J Obes. 2013;2013:616193. doi: 10.1155/2013/616193. Epub 2013 Mar 21. Review.</citation>
    <PMID>23577240</PMID>
  </reference>
  <reference>
    <citation>Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M, Pérez-Pérez R, Peral B, Cardona F, Fernández-Real JM, Tinahones FJ, Vendrell J. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One. 2012;7(11):e48605. doi: 10.1371/journal.pone.0048605. Epub 2012 Nov 5.</citation>
    <PMID>23139800</PMID>
  </reference>
  <reference>
    <citation>Goktas Z, Moustaid-Moussa N, Shen CL, Boylan M, Mo H, Wang S. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013 Jun 10;4:69. doi: 10.3389/fendo.2013.00069. eCollection 2013.</citation>
    <PMID>23772224</PMID>
  </reference>
  <reference>
    <citation>Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796-808.</citation>
    <PMID>14679176</PMID>
  </reference>
  <reference>
    <citation>García de la Torre N, Rubio MA, Bordiú E, Cabrerizo L, Aparicio E, Hernández C, Sánchez-Pernaute A, Díez-Valladares L, Torres AJ, Puente M, Charro AL. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008 Nov;93(11):4276-81. doi: 10.1210/jc.2007-1370. Epub 2008 Aug 19.</citation>
    <PMID>18713823</PMID>
  </reference>
  <reference>
    <citation>Leick L, Lindegaard B, Stensvold D, Plomgaard P, Saltin B, Pilegaard H. Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obesity (Silver Spring). 2007 Feb;15(2):356-63.</citation>
    <PMID>17299108</PMID>
  </reference>
  <reference>
    <citation>Panee J. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012 Oct;60(1):1-12. doi: 10.1016/j.cyto.2012.06.018. Epub 2012 Jul 4. Review.</citation>
    <PMID>22766373</PMID>
  </reference>
  <reference>
    <citation>Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients. Drugs R D. 2016 Sep;16(3):255-261.</citation>
    <PMID>27333994</PMID>
  </reference>
  <reference>
    <citation>Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001 Jan 18;409(6818):307-12.</citation>
    <PMID>11201732</PMID>
  </reference>
  <reference>
    <citation>Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond). 2008 Feb;114(4):275-88. doi: 10.1042/CS20070196. Review.</citation>
    <PMID>18194136</PMID>
  </reference>
  <reference>
    <citation>Vidal-Puig A, O'Rahilly S. Resistin: a new link between obesity and insulin resistance? Clin Endocrinol (Oxf). 2001 Oct;55(4):437-8. Review.</citation>
    <PMID>11678824</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9.</citation>
    <PMID>11238501</PMID>
  </reference>
  <reference>
    <citation>Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002 Dec;51(12):3391-9.</citation>
    <PMID>12453891</PMID>
  </reference>
  <reference>
    <citation>Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle. 2007 Apr 15;6(8):888-94. Epub 2007 Apr 11. Review.</citation>
    <PMID>17438370</PMID>
  </reference>
  <reference>
    <citation>Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. Review.</citation>
    <PMID>11244051</PMID>
  </reference>
  <reference>
    <citation>Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91.</citation>
    <PMID>7678183</PMID>
  </reference>
  <reference>
    <citation>Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995 Oct 6;270(40):23780-4.</citation>
    <PMID>7559552</PMID>
  </reference>
  <reference>
    <citation>Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol. 2003 Jun;177(3):351-5. Review.</citation>
    <PMID>12773114</PMID>
  </reference>
  <reference>
    <citation>Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. Review.</citation>
    <PMID>24026259</PMID>
  </reference>
  <reference>
    <citation>Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30. Review.</citation>
    <PMID>30449220</PMID>
  </reference>
  <reference>
    <citation>Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015 Sep;38(9):1638-42. doi: 10.2337/dc15-1380.</citation>
    <PMID>26294774</PMID>
  </reference>
  <reference>
    <citation>Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 15.</citation>
    <PMID>26078479</PMID>
  </reference>
  <reference>
    <citation>Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.</citation>
    <PMID>27082665</PMID>
  </reference>
  <reference>
    <citation>Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017 Aug;130:53-60. doi: 10.1016/j.diabres.2017.04.017. Epub 2017 May 18.</citation>
    <PMID>28570924</PMID>
  </reference>
  <reference>
    <citation>Erondu N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care. 2015 Sep;38(9):1680-6. doi: 10.2337/dc15-1251. Epub 2015 Jul 22.</citation>
    <PMID>26203064</PMID>
  </reference>
  <reference>
    <citation>Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019 Apr;18(4):295-311. doi: 10.1080/14740338.2019.1602116. Epub 2019 Apr 16. Review.</citation>
    <PMID>30933547</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1868.</citation>
    <PMID>24463454</PMID>
  </reference>
  <reference>
    <citation>Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes. 1988 Nov;37(11):1470-7.</citation>
    <PMID>3141236</PMID>
  </reference>
  <reference>
    <citation>Nogués Solán X, Sorli Redó ML, Villar García J. [Tools to measure treatment adherence]. An Med Interna. 2007 Mar;24(3):138-41. Spanish.</citation>
    <PMID>17590137</PMID>
  </reference>
  <reference>
    <citation>Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.</citation>
    <PMID>30882239</PMID>
  </reference>
  <reference>
    <citation>Wilding J, Bailey C, Rigney U, Blak B, Beekman W, Emmas C. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Ther. 2016 Dec;7(4):695-711. Epub 2016 Sep 1.</citation>
    <PMID>27585582</PMID>
  </reference>
  <reference>
    <citation>Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Häring HU, Stefan N, Fritsche A, Artunc F. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019 Apr 5;18(1):46. doi: 10.1186/s12933-019-0852-y.</citation>
    <PMID>30953516</PMID>
  </reference>
  <reference>
    <citation>Calapkulu M, Cander S, Gul OO, Ersoy C. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):284-288. doi: 10.1016/j.dsx.2018.09.005. Epub 2018 Sep 8.</citation>
    <PMID>30641713</PMID>
  </reference>
  <reference>
    <citation>Færch K, Amadid H, Nielsen LB, Ried-Larsen M, Karstoft K, Persson F, Jørgensen ME. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). BMJ Open. 2017 Jun 6;7(5):e013802. doi: 10.1136/bmjopen-2016-013802.</citation>
    <PMID>28592573</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Medico Nacional Siglo XXI IMSS</investigator_affiliation>
    <investigator_full_name>Aldo Ferreira Hermosillo</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Sodium-Glucose Transporter 2 Inhibitors</keyword>
  <keyword>PreDiabetes</keyword>
  <keyword>Obesity, Morbid</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

